Galaxy note 7 phone amid all those reports. This is samsungs worstever recall and could cost the company as much as 17 billion. Not coincidentally, apple shares rallying, relatively speaking, top gainer on the dow. John, we sort of set this up in the last hour. Now were starting to put this in context of giant recalls and corporate crises in history. Its difficult to gauge. Smart phone is this unprecedented consumer product, and millions of units, highly profitable. Only a couple of companies in the industry have been able to consistently make profits at it. Apple and samsung. Now youve got samsung stumbling. Equity that could be lost. Google pushing in, competitors at the lower end trying to push up. And its q4. If youve got a premium phone, you can sell it. If you dont, you just cant sell it. How many people shift to a lower profit Samsung Phone . How many people abandon android or how many switch to another android provider . Well have to see. Fte is comparing this to j j and tyleno
Announcing on cnbc he is out of apple shares. The dow component turning lower on his comments. Its down 2. 25 . Find out why he says this stock is no longer a nobrainer. Plus Health Insurer aetna delivered strong earnings. Mark bertolini is back to talk about the impact obamacare is having on his business and the structural changes he would like to see in obamacare to get them more involved in the process. Even as United Health is pulling back. Also its not just doughnuts, its a burrito like one of these, and this is a heavy burrito. That is heavy. Its still warm. It helped the Dunkin Donuts profit last quarter. It is the grande with two double ds. Well talk to nigel travis about how new menu items are helping the numbers. Ill pay you if you eat some. I cant. I just had chocolate. Takeover thursday is what we ended up with here. David faber has been covering all of it. Thats why hes still around today. Hes got the rundown on everything that happened. And youre right, it is. Its officia
SamaCare, a leading cloud-based patient access platform for specialty medications, today announced the closure of an oversubscribed $17 million Series B investment round.
SamaCare Secures $17M Series B Investment to Scale Specialty Drug Prior Authorization Platform tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
SamaCare, a leading cloud-based patient access platform for specialty medications, today announced the closure of an oversubscribed $17 million Series B investment round.